Flint Animal Cancer Center

Cancer Biology and Experimental Therapeutics

Dr. Thamm’s research centers on the characterization of important therapeutic targets in human oncology in spontaneous tumors of animal species sharing the environment with man, e.g. dogs and cats. Through the implementation of pharmacokinetically and pharmacodynamically intensive animal clinical trials, his laboratory seeks to provide meaningful translational information to inform and develop novel therapies with potential to impact the treatment of human and animal cancers. His current work focuses on tyrosine and serine/threonine kinase signaling, validation of biomarkers for novel therapeutics, and targeted therapy to enhance chemosensitivity.

Support and Service

  • In vitro and murine preclinical assays for drug activity and target inhibition in canine and feline cells

  • 30 validated canine and 4 feline tumor cell lines representing a variety of  common cancer types


  • Cell proliferation, apoptosis, migration, invasion, cell-cycle

  • Cytokine and growth factor ELISA

  • Western analysis, immunoprecipitation, real-time PCR

  • Immunohistochemistry, immunocytochemistry, immunofluorescence

  • Mouse xenograft experiments


  • Bio-Tek Synergy HT Multi-Mode Microplate Reader

  • Stratagene MX3000P real-time PCR workstation

  • Xenogen IVISTM luciferase and GFP in vivo imaging system

  • Bio-Rad ChemiDoc XRS Gel Imaging System

Select recent publications (from over 120):

Saba CF, Vickery KR, Clifford CA, Burgess KE, Phillips BS, Vail DM, Wright Z, Morges MA, Fan TM, Thamm DH. Rabacfosadine for relapsed canine B-cell lymphoma: efficacy and adverse event profiles of two different doses. Vet Comp Oncol, epub ahead of print 2017. doi: 10.1111/vco.12337. PMID: 28891260

Laver T, London CA, Vail DM, Biller BJ, Coy J, Thamm DH. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma. Vet Comp Oncol, epub ahead of print 2017. doi: 10.1111/vco.12328. PMID: 28621057

Fowles J, Dailey D, Gustafson DL, Thamm DH, Duval DL. The Flint Animal Cancer Center (FACC) canine tumor cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine. Vet Comp Oncol 15(2): 481-492, 2017. PMID: 27197945

Burton JH, Venable RO, Vail DM, Williams LE, Clifford CA, Axiak-Bechtel S, Avery AC, Thamm DH. Pulse-administered toceranib phosphate plus lomustine for the treatment of unresectable canine mast cell tumors. J Vet Intern Med 29(4): 1098-1104, 2015. PMID: 26119008

Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in dogs with spontaneously occurring lymphoma. Autophagy 10(8): 1415-1425, 2014. PMID: 24991836

Halsey CHC, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia) in canine mast cell tumor. BMC Vet Res 10: 105, 2014. PMID: 24885200

Thamm DH, Grunerud KK, Rose BJ, Vail DM, Bailey SM.  Mutagen sensitivity as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study. PLoS ONE 8(7): e69192, 2013. PMID: 23935952